We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Scotiabank to Buy BBVA Chile to Deepen Reach in Latin America
Read MoreHide Full Article
The Bank of Nova Scotia (BNS - Free Report) aims to become the third-largest private bank in Chile with the acquisition of Banco Bilbao Vizcaya Argentaria, S.A.’s (BBVA - Free Report) 68.19% stake in BBVA Chile for about $2.2 billion (CAD$ 2.9 billion).
BBVA will accept the binding offer submitted by Scotiabank if the Said family — BBVA's minority partner with the remaining stake — chooses not to exercise its Right of First Refusal. On completion of the deal, Scotiabank's Common Equity Tier (CET) 1 capital ratio is expected to be impacted by nearly 1%.
Notably, the Said family has the right to sell its stake in BBVA Chile on the same terms to Scotiabank, per the tag-along rights it has under the shareholders agreement of BBVA Chile. Scotiabank’s CET 1 ratio would be impacted by about 1.35% if the bank is successful in purchasing all the shares of BBVA Chile.
The transaction is likely to raise Scotiabank's market share in Chile to nearly 14%, almost double of what is had before. BBVA Chile with assets and more branches than Scotiabank will deepen latter’s reach in Latin America. This is in line with the bank’s aim to expand operations in the region.
Though the stock was down nearly 2.5% in the last trading session, the Canadian Bank reported strong results for the fiscal 2017.
Adjusted earnings per share were up 8% on a year-over-year basis. Also, it recorded improved revenues, which were partially offset by a fall in trading revenues due to low volatility in the markets compared to the last fiscal year.
Further, its CET 1 ratio rose five basis points to 11.5%. This indicates the bank’s sound financial position and leaves no doubts for the impending acquisition.
Shares of Bank of Nova Scotia have gained 14.6% year to date, underperforming the 18.4% rally for the industry it belongs to.
Currently, the stock carries a Zacks Rank #4 (Sell).
Bank of N.T. Butterfield & Son’s Zacks Consensus Estimate for current-year earnings has been revised 2.2% upward in the last 60 days. The company’s share price has risen almost 24.6% year to date.
Credicorp’s current-year earnings estimates have been revised slightly upward over the last 60 days. Also, its shares have gained 35.7% so far this year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Scotiabank to Buy BBVA Chile to Deepen Reach in Latin America
The Bank of Nova Scotia (BNS - Free Report) aims to become the third-largest private bank in Chile with the acquisition of Banco Bilbao Vizcaya Argentaria, S.A.’s (BBVA - Free Report) 68.19% stake in BBVA Chile for about $2.2 billion (CAD$ 2.9 billion).
BBVA will accept the binding offer submitted by Scotiabank if the Said family — BBVA's minority partner with the remaining stake — chooses not to exercise its Right of First Refusal. On completion of the deal, Scotiabank's Common Equity Tier (CET) 1 capital ratio is expected to be impacted by nearly 1%.
Notably, the Said family has the right to sell its stake in BBVA Chile on the same terms to Scotiabank, per the tag-along rights it has under the shareholders agreement of BBVA Chile. Scotiabank’s CET 1 ratio would be impacted by about 1.35% if the bank is successful in purchasing all the shares of BBVA Chile.
The transaction is likely to raise Scotiabank's market share in Chile to nearly 14%, almost double of what is had before. BBVA Chile with assets and more branches than Scotiabank will deepen latter’s reach in Latin America. This is in line with the bank’s aim to expand operations in the region.
Though the stock was down nearly 2.5% in the last trading session, the Canadian Bank reported strong results for the fiscal 2017.
Adjusted earnings per share were up 8% on a year-over-year basis. Also, it recorded improved revenues, which were partially offset by a fall in trading revenues due to low volatility in the markets compared to the last fiscal year.
Further, its CET 1 ratio rose five basis points to 11.5%. This indicates the bank’s sound financial position and leaves no doubts for the impending acquisition.
Shares of Bank of Nova Scotia have gained 14.6% year to date, underperforming the 18.4% rally for the industry it belongs to.
Currently, the stock carries a Zacks Rank #4 (Sell).
A couple of better-ranked foreign bank stocks are Bank of N.T. Butterfield & Son Limited (NTB - Free Report) and Credicorp Ltd (BAP - Free Report) . Both these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bank of N.T. Butterfield & Son’s Zacks Consensus Estimate for current-year earnings has been revised 2.2% upward in the last 60 days. The company’s share price has risen almost 24.6% year to date.
Credicorp’s current-year earnings estimates have been revised slightly upward over the last 60 days. Also, its shares have gained 35.7% so far this year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>